This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...

Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as ...

Recent polling shows oncologists changing inclination in treatment for mHSPC based on tolerability profiles.

Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute myeloid leukemia (AML), according to a new study by researchers at Penn ...

The optimal time to measure PSA response to treatment is the one that best predicts metastatic hormone-sensitive prostate cancer (mHSPC) progression.

Actinium Pharmaceuticals, Inc. , a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class Actinium-225 (AC-225) ...

Investor attention is shifting toward a key scientific conference as shares of biotechnology firm Veru Inc. trade quietly. The company is scheduled to deliver multiple presentations on its lead drug ...

Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says one more factor should be considered – chronological age. The study, ...

Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says one more factor should be considered—chronological age. Subscribe to our ...